ICU Medical Reports Improved Profitability in Q2 2025

ICU Medical ( (ICUI) ) has released its Q2 earnings. Here is a breakdown of the information ICU Medical presented to its investors.

ICU Medical, Inc. is a global leader in the development, manufacture, and sale of innovative medical products, primarily focusing on infusion systems, infusion consumables, and critical care products for hospital and home care settings. Headquartered in San Clemente, California, the company is known for its commitment to quality, innovation, and value.

ICU Medical recently released its financial results for the second quarter of 2025, reporting a revenue of $548.9 million, a decrease from $596.5 million in the same period the previous year. Despite the drop in revenue, the company achieved a GAAP net income of $35.3 million, a significant improvement from a net loss of $21.4 million in the second quarter of 2024.

Key financial highlights include a GAAP gross profit of $208.1 million, slightly up from $207.4 million in the prior year, with a gross margin increase to 38% from 35%. The adjusted diluted earnings per share rose to $2.10 from $1.56, and adjusted EBITDA improved to $100.3 million compared to $91.3 million in the previous year. The company’s product line performance showed growth in consumables and infusion systems, while the vital care segment saw a decline.

Looking ahead, ICU Medical has updated its fiscal year 2025 guidance, adjusting its GAAP net loss expectations and narrowing its adjusted EBITDA range. The company remains focused on strategic initiatives and operational efficiencies to drive future growth.

In conclusion, ICU Medical’s financial performance in the second quarter of 2025 reflects a positive turnaround in profitability, despite revenue challenges. The company’s management remains cautiously optimistic about the future, with a focus on maintaining its leadership position in the medical products industry.